HCV Protease Inhibitor Hydrate III Stability via Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infection, particularly targeting HCV protease activity, face challenges in stability and efficacy of therapeutic compounds, necessitating the development of more stable and effective inhibitors.
Innovation Solution
The development of Compound A in various hydrate forms and salt forms, characterized by specific X-ray diffraction patterns, thermogravimetric analysis, and differential scanning calorimetry, which are more stable and effective in inhibiting HCV activity, including the use of acetone and water in preparing Hydrate III.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HCV protease inhibitors are used, then HCV protease activity can be inhibited, but the compounds suffer from poor stability and reduced therapeutic efficacy
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical state of Compound A through hydration. Different hydrate forms (hydrate I, hydrate II, hydrate III, hydrate IV, hydrate V, hydrate VI) are discovered and characterized, each with distinct stability profiles. Hydrate III is identified as having optimal stability properties for therapeutic use, resolving the contradiction between compound stability and therapeutic efficacy.
Solution Approach 2:
The patent employs composite material principles by creating hydrate forms of Compound A, which are composite structures consisting of the active pharmaceutical ingredient combined with water molecules in specific stoichiometric ratios. These hydrate complexes exhibit enhanced stability compared to the anhydrous form, while maintaining the desired HCV protease inhibition activity.
2Stability of the object's composition
If multiple crystal forms and hydrates are developed, then compound stability is improved, but the complexity of characterization and manufacturing increases
Solution Approach 1:
The patent applies segmentation by systematically characterizing each hydrate form as a distinct entity with unique properties. Six different hydrate forms are identified and individually characterized using multiple analytical techniques (XRPD, TGA, DSC, NMR, IR). This segmented approach allows for clear differentiation and selection of the most suitable hydrate form (hydrate III) for further development, managing the complexity through systematic organization.
Solution Approach 2:
The patent uses parameter changes to distinguish between different hydrate forms based on their physical and chemical properties. Each hydrate form exhibits distinct X-ray diffraction patterns, thermogravimetric profiles, differential scanning calorimetry curves, NMR spectra, and infrared absorption characteristics. These parameter variations enable clear identification and characterization of each form, managing complexity through systematic parameter-based differentiation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable forms of Compound A, particularly Hydrate III, demonstrate enhanced stability and effectiveness in inhibiting HCV activity, providing a therapeutic option with improved stability and efficacy for treating HCV infection.
Implementation Method 1
methods of making Hydrate III from Compound A using acetone and water
Implementation Method 2
characterized by specific X-ray diffraction patterns
Implementation Method 3
characterized by specific X-ray diffraction patterns, thermogravimetric analysis, and differential scanning calorimetry
Implementation Method 4
characterized by specific X-ray diffraction patterns, thermogravimetric analysis, and differential scanning calorimetry
Data Source
AI summary
The present invention relates to different forms of a HCV inhibitory compound.